@RAH00084@tom_the_bomb__@Blueberrymgmnt We could be the perfect case study.
‘New biotech with exceptionally promising technology sailed through clinical trials as we were able to identify tumours that were the most susceptible to treatment’
I can see it now.
Roll on next year!
@ZosoGraffiti@neutronicLSE Where has this fantasist scenario come from?
The company are shelling out a lot of money to apparent financial wizards and we now need a black book contact to save the SP..
I wonder if Mahmud Kamani is available?
Oh wait..
@Tom_The_Bomb__ If #AVA6000 ever gets FDA approval it becomes the standard of care.
Dox will become know as the partially successful origin nothing more.
AVA6000 can be used for longer, it’s less toxic you’d be mad not to specify it… unless of course you’d prefer cardiovascular toxicities